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Abstract Hepatocellular carcinoma (HCC) is the third-
leading cause of cancer-related mortality worldwide.
Although hepatitis B still remains the most common risk
factor worldwide, chronic hepatitis C virus (HCV) infec-
tion is the driving force for the increased incidence of HCC
especially in Western countries and Japan. In hepatitis B
virus (HBV)-endemic areas, after successful vaccination
programs against HBV, chronic HCV infection is now
emerging as an important cause of chronic liver diseases.
Unlike patients with chronic hepatitis B, those with chronic
hepatitis C (CHC) develop HCC in the presence of estab-
lished cirrhosis in most cases. However, a significant
minority of CHC develops HCC in the absence of cirrhosis.
Although HCV is a RNA virus with little potential for
integrating its genetic material into host genome, various
HCV proteins, including core, envelope, and nonstructural
proteins, have oncogenic properties by inducing oxidative
stress, disturbing cellular regulatory pathways associated
with proliferation and apoptosis, and suppressing host
immune responses. Overall, a combination of virus-spe-
cific, host genetic, environmental, and immune-related
factors are likely to determine progression to HCC. Strat-
egies aimed at eliminating the virus may provide oppor-
tunities for effective prevention of the development of
HCC. Pegylated interferon plus ribavirin therapy appears to
be effective at reducing the risk of HCC in patients who
achieve sustained virologic responses. In summary, with
the emerging importance of CHC, mechanisms of HCV-
associated hepatocellular carcinogenesis should be clarified
to provide insight into advanced therapeutic and preventive
approaches, which eventually decrease the incidence and
mortality of HCC.
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Introduction
Hepatocellular carcinoma (HCC), accounting for [5 % of
cancers globally, is ranked as the 6th most common cancer
and the 3rd leading cause of cancer-related death world-
wide. The incidence of HCC may continue increasing over
the next 20 years and to peak around 2030 [1–3]. Etio-
logically, chronic hepatitis B (CHB) still remains the most
common risk factor for HCC worldwide, however, after
successful vaccination program against hepatitis B virus
(HBV), chronic hepatitis C (CHC) has become an impor-
tant cause of chronic liver diseases (CLDs) in both Western
countries and the Asia–Pacific region. Nowadays, there are
an estimated 170 million infected with hepatitis C virus
(HCV) globally, and the incidence of HCC and HCV has
increased in recent decades, suggesting an etiologic link. In
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Korea, about 10 % of cirrhosis and 12–17 % of HCC were
due to HCV infection [1–3]. Even though the risk of
transfusion-related HCV infection is almost zero in
developed countries, infections via injection drug use and
certain insanitary practices, such as acupuncture, tattooing,
and body piercing, have become an emerging medical
issue. HCC is a common cause of liver-related death
among HCV-infected persons, developing predominantly
in those with cirrhosis. Nevertheless, several studies have
reported that HCC occurs in persons with bridging fibrosis
without definite cirrhosis, although far less commonly [4–
8]. To date, there are new insights into HCV-related
hepatocarcinogenesis.
This article reviews hepatocarcinogenesis and measures
for predicting and preventing the development of HCC in
patients with chronic HCV infection.
Hepatocarcinogenesis in HCV
Since HCV lacks reverse transcriptase activity unlike
HBV, it does not integrate into the host genome. Further-
more, as HCV is a completely cytoplasmic-replicating
virus, the main hypothesis for carcinogenesis is that it
occurs via indirect pathways through the effects of chronic
inflammation, oxidative stress and subsequent hepatocel-
lular injury. This assumption is supported by the fact that
the presence of cirrhosis is almost a prerequisite for HCC
development [9]. As a matter of fact, this is why patients
with CHC are less likely to be candidates for hepatic
resection in terms of preoperative liver functions and tumor
locations, multiplicity, and invasiveness and have a higher
cumulative recurrence rate, even after surgery, than those
with CHB [10–12].
However, it is unlikely that necro-inflammation alone is
sufficient to cause HCC. As a matter of fact, a significant
minority arises in the absence of cirrhosis and other lines of
evidence suggest that direct, virus-specific mechanisms
may be involved [13, 14]. Recent studies have suggested
that various HCV proteins, including the core, envelope,
and nonstructural proteins, exert direct oncogenic effects
by inducing oxidative stress, disturbing cellular regulatory
pathways associated with proliferation and apoptosis, and
suppressing host immune responses [13–15] (Fig. 1). HCV
core protein, a 21-kDa nucleocapsid protein involved in
binding viral RNA, is involved not only in viral particle
assembly and generation of complete virions, but also in
cell signalling, transcription activation, apoptosis, lipid
metabolism and transformation [16, 17]. There are several
hypotheses concerning its role in carcinogenesis [13, 18–
22]. First, HCV core protein has been shown to induce
reactive oxygen species even in the absence of inflamma-
tion. The oxidative stress may decrease metabolic pro-
cesses within mitochondria, with a decline in microsomal
triglyceride transfer protein activity, resulting in the
development of steatosis [14, 23–26]. Second, it has also
Fig. 1 A schematic display of HCV-specific hepatocarcinogenesis.
Various HCV proteins, including the core, nonstructural proteins
(NS3, NS5A), and E2 exert direct oncogenic effects by inducing
oxidative stress, disturbing cellular regulatory pathways associated
with proliferation and apoptosis, and suppressing host immune
responses. HCV hepatitis C virus, HCC hepatocellular carcinoma
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been shown to affect cellular regulatory pathways. For
example, it can bind to p53 and pRb, tumor suppressor
proteins and modulate the expression of p21/Waf, which is
involved in cell cycle control, and interact with cytoplasmic
signal transduction molecules to regulate transcription [16,
27]. More recently, HCV core protein seems to increase the
serine phosphorylation of insulin receptor substrate (IRS)-1
and to activate c-Jun N-terminal kinase signaling and the
proteasome activator 28c, all of which are associated with
insulin resistance [28–30]. Such hyperinsulinemia from
insulin resistance—by its action on hepatic stellate cells,
extracellular matrix, endothelial cells or connective growth
factors—not only can accelerate the progression of fibrosis
[31, 32], but also can increase accumulation of free fatty
acids in the liver, leading to activation of some kinases, such
as protein kinase C delta, inhibitor kappa B kinase, JNK, or
mammalian target of rapamycin (mTOR) that are known to
promote carcinogenesis [33, 34].
Apart from the core proteins, other HCV proteins have
also been shown to contribute to hepatocarcinogenesis. For
example, NS3 can promote hepatocarcinogenesis by its
interaction with certain proteins, such as p21 and p53,
whereas NS5A can also interact with cellular signalling
components and regulatory protein kinases, leading to the
suppression of the host immune response and inhibition of
apoptosis [35–38]. Furthermore, the truncated form of
HCV NS5A can become localized to the nucleus to act as a
transcriptional activator. Besides, The E2 protein can
interact with CD81 and inhibit T and NK cells, thereby
promoting cell survival and proliferation.
Taken together, complex interactions of the various
HCV proteins with host cell factors have also been shown
to be sufficient to induce hepatocarcinogenesis, through
alteration of cellular signaling cascades involved in cell
metabolism and division [13, 14]. Overall, the synergism of
indirect chronic inflammation and direct virus-host cell
interactions are likely to determine the progression to HCC
in patients with CHC.
How to predict HCC development?
As aforementioned, although HCV-specific hepatocarci-
nogenesis had been spotlighted recently, chronic inflam-
mation and oxidative stress from immune responses against
infected hepatocytes and resultant hepatic fibrosis still
remain the major pathogenesis for development of HCC.
Since such processes facilitate the accumulation of genetic
alterations simultaneously, approximately half of cirrhotic
nodules harbor chromosomal abnormalities and a loss of
alleles [38]. Thus, an accurate assessment of overall
fibrotic burden is an important prerequisite for risk strati-
fication of HCC development.
Recently, liver stiffness (LS) measured noninvasively by
transient elastography (TE) has been reported to be well
correlated with histologically assessed liver fibrosis degree
[39–43]. The principle of TE is based on the principle that
the propagation velocity of a wave through a homogenous
tissue is proportional to its elasticity, so livers with
increasing degrees of scarring have decreasing elasticity
and that a shear wave propagating through stiffer material
would progress faster than in one with more elastic mate-
rial [41, 44]. From this viewpoint, the role of TE for risk
stratification of development of HCC have been evaluated
to date [45, 46]. The first large prospective cohort study of
866 Japanese patients with CHC tested whether TE can
predict the future development of HCC [45, 46]. During a
mean follow-up of 3 years, 77 patients developed HCC. By
multivariate analysis, together with age, male gender, and
clinical cirrhosis, stratified TE value was identified as an
independent risk factor for HCC development, with relative
risks of 16.7, 20.0, 25.6, and 45.5 for TE values of 10–15,
15–20, 20–25, and [25 kPa, respectively, versus an TE
value of \10 kPa as the reference and the cumulative
incidence of HCC showed a step-wise increase according
to stratified TE value. Interestingly, in this study, even
patients with not so high level of TE (10–15 kPa) were still
more subject to HCC development with an adjusted HR of
16.7, compared to those with a TE value \10 kPa. Overall,
the fibrotic burden estimated by TE has shown the potential
for a clinical role in predicting the development of HCC
and, in part, demonstrated superior performance to histol-
ogy and other noninvasive tools [47–52]. This is most
likely due to the wider dynamic range of TE values in the
evaluation of liver cirrhosis. In fact, as the stage of ‘‘cir-
rhosis’’ has to date been defined by histopathological evi-
dence of one or two qualitative categories (METAVIR
stage F4 or ISHAK S5–S6), or more generally by the
presence of so-called ‘‘regenerative’’ or ‘‘cirrhotic nod-
ules,’’ an interval scale cannot be used in this setting.
However, the degree of liver fibrosis may vary widely
among patients in this category, and the risk of HCC may
not be uniform. Thus, in this regard, because TE value,
expressed in kPa as a continuous variable, has a wide
dynamic range within the cirrhotic stage from the cutoff
level from non-cirrhosis (15–17 kPa) to the upper mea-
surement limit of present devices (75 kPa), it would seem
to be a more reasonable tool for detailed prognostication.
Prevention of development of HCC in patients
with chronic HCV infection
The first prevention for HCV-associated HCC is avoidance
of chronic HCV infection. However, unfortunately, vacci-
nation against de novo HCV infection is currently not
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available, in contrast to HBV infection. Accordingly, the
next step to reduce HCV-associated HCC is the effective
eradication of HCV from the host using antiviral therapy
from the viewpoint of the 2nd prevention. For several
decades, interferon (IFN)-based therapy appears to be
effective at both controlling HCV infection and reducing
the risk of HCC [46]. Its preventive effect is the highest
among patients who achieve sustained virologic response
(SVR). A meta-analysis found that SVR was associated
with a 79 % (95 % CI 0.73–0.84) reduction in the risk of
development of HCC by patients with HCV-related cir-
rhosis. Such treatment to eradicate HCV is contributable to
reduce hepatic fibrosis and cirrhosis, and prevention of
HCC [53–55]. The cumulative incidences of HCC in
treated and control patients with cirrhosis were 7.8 and
24.2 %, respectively (hazard ratio [HR], 0.45; 95 % con-
fidence interval [CI], 0.24–0.83). Table 1 summarizes
several RCTs where the risk of developing HCC had been
reduced after successful antiviral therapy. A recent study
suggested the additional benefit of IFN-based therapy
among patients with cirrhosis even though they did not
have a SVR to therapy. However, several large scaled
randomized trials (HALT-C, COPILOT, and EPIC) have
demonstrated that maintenance pegylated (PEG)-IFN fails
to prevent HCC in patients with HCV-related cirrhosis
among nonresponders. Lok et al. [56] reported that exten-
ded follow-up of the HALT-C Trial cohort for a median of
6.1 years showed a modest benefit of long-term PEG-IFN
therapy in reducing the incidence of HCC in patients with
hepatitis C and cirrhosis but not in those with advanced
pre-cirrhotic fibrosis. HCV therapy has been revolutionized
recently by development and approval of direct-acting
antiviral agents (DAA), yielded by extensive researches
of the crystal structure of several critical viral proteins
[57–59]. In the year 2011, the first two DAAs, telaprevir
(Incivek; Vertex Pharmaceuticals Cambridge, MA, USA)
and boceprevir (Victrelis; Merck & Co Whitehouse
Station, NJ, USA), both inhibiting the NS3/4A protease,
had been approved for use in patients with chronic HCV
infection with genotype 1 and marked the beginning of a
new era in HCV therapy. Several clinical trials demon-
strated that these two drugs were potent for the efficacy
and safety in treatment-naı¨ve genotype 1 HCV infection
[60–62]. The addition of telaprevir and boceprevir to the
standard PEG-IFN and ribavirin regimen has provided a
major advance in the treatment-naı¨ve and –experienced
genotype 1 patients. Moreover, with the improvement of
SVR rate with these new drugs, the rate of HCC development
will be lower accordingly.
Although HCC has been treated curatively, such patients
are still at risk of developing HCC in the future. As a
matter of fact, more than half of the patients successfully
treated with surgical resection experience recurrent HCCs
within 5 years of surgery, despite successful resection.
Therefore, for such ‘‘high-risk subjects’’, so called the 3rd
prevention might be beneficial. Recurrences should be
differentiated into early and late recurrences. Early recur-
rences are the result of occult metastasis left behind after
resection. Such tumors will usually become apparent
within 2 years of surgery. In contrast, late or de novo
recurrences are new, typically occurring more than 2 years
after surgery, as the result of the underlying procarcino-
genic liver disease, caused by cirrhosis itself or HCV.
There have been several randomized controlled trials
(RCTs) and at least one meta-analysis about effect of IFN
therapy after resection of HCC, most of which consistently
favors the use of IFN-based therapy [63, 64]. A meta-
analysis by Singal et al. [63] showed that IFN-based ther-
apy could reduce the risk of developing a new focus of
HCC and that the benefit of IFN for HCC recurrence was
stronger with SVR compared with non-responders [0.19
(0.06–0.60); P = 0.005]. However, notably, the benefit of
Table 1 Summary of randomized controlled trials on incidence of HCC among patients with HCV infection
Author (year) n Control group (untreated) Treatment group P value
No. HCC/no. cases (%) No. HCC/no. cases (%)
Mazzella et al. [77] 284 9/92 9.8 5/193 2.6 \0.05
Valla et al. [78] 99 9/52 17 5/47 11 NS
Bernandinello et al. [79] 61 1/23 4.3 2/38 5.3 NS
Nishiguchi et al. [80] 90 33/45 73 12/45 27 \0.05
Planas et al. [81] 50 2/21 9.5 1/19 5.3 NS
Azzaroli et al. [82] 60 9/30 30 0/30 0 \0.05
Soga et al. [83] 133 7/30 23.3 5/103 4.9 \0.05
Fartoux et al. [84] 102 6/51 11.8 6/51 11.8 NS
Lok et al. [56] 427 34/220 15.5 14/207 6.8 \0.05
Bruix et al. [85] 626 4/315 1.3 4/311 1.3 NS
HCC hepatocellular carcinoma, HCV hepatitis C virus, NS non significance
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antiviral therapy and SVR is primarily limited to preven-
tion of late recurrence.
Taken together, since recent lines of evidence suggest
the potential roles of virus-specific mechanisms [16, 17],
the importance of an effective eradication of HCV from
host can not be overestimated to reduce the risk of de novo
development of HCC.
Management of HCC
Although surgical resection or local ablative therapies such
as radiofrequency ablation (RFA) and percutaneous ethanol
injection (PEI) achieve the best outcomes with a 5-year
survival rate of 60–70 % in patients treated during early
stages, only about 30 % are amenable to potentially cura-
tive treatments. Eventually, most patients are eligible for
only palliative treatments in hope of prolonging life, and a
multidisciplinary therapeutic approach is required for
optimal treatment outcome. Nowadays, the molecular
target agents have been spotlighted for several years.
Sorafenib, an oral multikinase inhibitor blocking tumor cell
proliferation and tumor angiogenesis by inhibiting serine/
threonine kinase and several receptor tyrosine kinases such
as vascular endothelial growth factor receptors (VEGFRs)
2 and 3, platelet-derived growth factor receptor-b, Fms-
related tyrosine kinase (Flt), and c-kit had shown the pro-
ven survival benefits compared to the best supportive care
through the two large trials [65–68].
In 2008, the SHARP trial in which 602 patients with
advanced HCC were randomized to receive either sorafenib
400 mg b.i.d. (n = 299) or a placebo (n = 303) demonstrated
that overall survival (OS) was significantly prolonged in
sorafenib-treated patients compared with placebo group (10.7
vs. 7.9 months, respectively, p \ 0.001) [65]. Furthermore,
sorafenib significantly improved the time to disease progres-
sion (TTP) compared to placebo (5.5 vs. 2.8 months,
respectively, p \ 0.001). Following the SHARP trial, Cheng
et al. [69] published a large-scale Asia–Pacific Phase III ran-
domized trial of sorafenib versus placebo in 226 Asian
patients (150 received sorafenib and 76 received placebo)
from China, South Korea, and Taiwan study. This study had
similar aims and design as the SHARP trial. The median OS
was 6.5 vs. 4.2 months in the sorafenib and placebo groups,
respectively (p = 0.014), whereas the median TTP was 2.8
vs. 1.4 months, respectively (p \ 0.001). In this study, com-
mon drug-related adverse events included hand-foot skin
reactions (45.0 %), diarrhea (25.5 %), alopecia (24.8 %),
fatigue (20.1 %), rash or desquamation (20.1 %), hyperten-
sion (18.8 %), and anorexia (12.8 %). However, compared to
the SHARP trial, more patients with hand-foot skin reactions
and fewer with diarrhea were observed in the Asia–Pacific
study [65, 69].
Notably, compared with the SHARP trial, the absolute
median OS and TTP were shorter in the Asia–Pacific study,
which might presumably have resulted from the difference
in the baseline characteristics of enrolled subjects, sug-
gesting the higher percentage of more advanced disease in
the Asia–Pacific study. Similarly, a pilot study where 97
HCC patients with either main portal vein invasion or
extrahepatic spread were treated with sorafenib demon-
strated that the median TTP and OS were 2.2 and
Table 2 Comparison of the
SHARP and Asia–Pacific trials
Unless otherwise indicated, the
values are percentages
ECOG PS Eastern Cooperative
Oncology Group performance
score, HBV hepatitis B virus,
HCV hepatitis C virus, BCLC
Barcelona Clinic liver cancer,
OS Overall survival, TTP time
to progression
a Patients in the sorafenib group
were compared
SHARP (n = 602) Asia–Pacific (n = 226)
Baseline characteristics
Median age (range), years 67 (21–89) 51 (23–86)
ECOG PS, 0/1/2 54/38/8 26/69/5
Etiology, HBV/HCV 18/28 73/8
Extrahepatic spread 51 69
BCLC stage, B/C 17/82 4/96
End pointa
Median OS (months) 10.7 6.5
Median TTP (months) 5.5 2.8




Disease control rate 43 35.3
Adverse eventsa
Hand-foot skin reaction 21 67
Hypertension 5 28
Alopecia 14 37
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7.7 months, respectively and that therapy was stopped due
to adverse events or cost burden in 34 % of the patients
[70]. Another Korean study also reported that the median
TTP was 9.1 weeks [71]. The detailed differences between
the two trials are summarized in Table 2.
Taken together, sorafenib became standard therapy for
the treatment of advanced HCCin Asia as well as Western
countries. However, the prognosis of HCC is generally
worse than in Western countries. Furthermore, the high
cost of sorafenib is an obstacle to its widespread use in
clinical practice [69, 72–75]. Nevertheless, sorafenib has a
firm position at the core of HCC therapy and its indications
are anticipated to widen in the near future to intermediate
HCC or as an adjuvant agent with or without a combination
modality. A rational approach based on cost, quality of life,
and survival will be urgently needed.
Besides, other small molecules, such as brivanib and
erlotinib, and monoclonal antibodies, such as bevacizumab
and cetuximab, are currently being studied in patients with
HCC. Furthermore, the clinical implication of other con-
ventional treatment modalities, including hepatic arterial
infusion chemotherapy or localized concurrent chemora-
diation therapy for advanced HCC, should be reilluminated
in comparison with the novel molecular target agent and
the combined methods should be considered to improve
clinical outcomes [75, 76].
Conclusions
In Asia, a nationwide vaccination program would even-
tually decrease HBV-related HCC. Conversely, HCV
infection has recently become a significant problem,
leading to increase of HCV-related HCC. With the
emerging importance of CHC as an etiology for CLDs,
there is a pressing need for further research on HCV-
associated carcinogenesis to identify the steps from
chronic HCV infection to cancer, and that can help
developing of prevention, early screening, and treatment.
HCV-associated hepatocellular carcinogenesis should be
clarified to provide insight into advanced therapeutic and
preventive approaches for HCC, which will eventually
decrease development of HCC risk and improved survival
outcomes. Furthermore, continuous efforts have been put
into finding new targets and molecular pathways for pos-
sible new drug development.
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